SLC5A5 and thyroid cancer: Triehostatin A (TSA), a histone deacetylase inhibitor, could significantly increase the expression of NIS, induce the redifferentiation, and restore 131I uptake in three thyroid cancer cell lines (TPC-1, XTC-1, and FTC-133) [141].